Dhondt J L, Farriaux J P, Sailly J C, Lebrun T
Centre Régional de Dépistage des Maladies Métaboliques de l'Enfant, Faculté de Médecine, Lille, France.
J Inherit Metab Dis. 1991;14(4):633-9. doi: 10.1007/BF01797933.
A comparison between the cost of identification and care of patients with phenylketonuria (PKU) and congenital hypothyroidism (CH) and the expenditure for the care of untreated retarded patients has been established on the basis of the activity of the Nord-Pas-de-Calais regional screening centre and of interviews with patients' families. The analysis yields a benefit-cost ratio of 6.6 for PKU and 13.8 for CH prophylaxis. However, cost-benefit varies depending on the economic partner, i.e. the patient's family, Social Security or Administration.
根据北加莱海峡地区筛查中心的活动以及与患者家庭的访谈，对苯丙酮尿症（PKU）和先天性甲状腺功能减退症（CH）患者的识别与护理成本，以及未治疗的智力迟钝患者的护理费用进行了比较。分析得出，PKU的效益成本比为6.6，CH预防的效益成本比为13.8。然而，成本效益因经济合作伙伴而异，即患者家庭、社会保障部门或行政部门。
